Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Neurogenesis and Regeneration of Nervous Tissue01:15

Neurogenesis and Regeneration of Nervous Tissue

2.1K
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multitarget therapeutic potential of sulforaphane in ethidium bromide-induced neurotoxicity in multiple sclerosis-like pathology: comparison with omaveloxolone and dimethyl fumarate on neuroprotection and systemic recovery.

Scientific reports·2026
Same author

Combined Puerarin and Magnesium Acetyl Taurate Intervention Mitigates Autism-Like Pathology Through Glutamatergic and MAPK Pathway Regulation.

Neurochemical research·2026
Same author

Converging neurotrophic-immune signaling in autism spectrum disorder: integrative roles of klotho, GDNF/GFRA-1, IGF-1 and GLP-1 pathways.

Metabolic brain disease·2026
Same author

Advancing the Frontiers of Multiple Sclerosis Management: Emerging Immunotherapeutic Strategies.

Current neurovascular research·2026
Same author

Rituximab beyond oncology: targeting B-cell-mediated immunomodulatory therapy in neurodegenerative and neuropsychiatric disorders.

Immunopharmacology and immunotoxicology·2026
Same author

Enhanced Neurophysiological Benefits of Magnesium-Acetyl-Taurate Over Magnesium-L-Threonate: A Comparative pre-clinical Study on Bioavailability, Synaptic Plasticity and Cognitive Functions.

Neuromolecular medicine·2026

Related Experiment Video

Updated: May 1, 2026

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.2K

Raloxifene Beyond Osteoporosis: Unlocking Neurorestoration Through Remyelination, Inflammatory Regulation, and

Chandrayee Banerjee1, Rohit Kumar Singh1, Sidharth Mehan1

  • 1Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India (Affiliated to IK Gujral Punjab Technical University, Jalandhar, Punjab, 144603), India.

International Immunopharmacology
|April 29, 2026
PubMed
Summary

Raloxifene, a SERM, shows neuroprotective potential for Alzheimer's, Parkinson's, and other CNS disorders by modulating estrogen receptors. Further clinical validation is needed to establish its therapeutic role in neurological conditions.

Keywords:
Estrogen receptor modulationNeurodegenerative disordersNeuroprotectionNeuropsychiatric disordersRaloxifeneSelective Estrogen receptor modulator (SERM)

More Related Videos

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

29.7K
Implantation of Miniosmotic Pumps and Delivery of Tract Tracers to Study Brain Reorganization in Pathophysiological Conditions
10:32

Implantation of Miniosmotic Pumps and Delivery of Tract Tracers to Study Brain Reorganization in Pathophysiological Conditions

Published on: January 18, 2016

14.9K

Related Experiment Videos

Last Updated: May 1, 2026

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.2K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

29.7K
Implantation of Miniosmotic Pumps and Delivery of Tract Tracers to Study Brain Reorganization in Pathophysiological Conditions
10:32

Implantation of Miniosmotic Pumps and Delivery of Tract Tracers to Study Brain Reorganization in Pathophysiological Conditions

Published on: January 18, 2016

14.9K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Endocrinology

Background:

  • Raloxifene, a selective estrogen receptor modulator (SERM), is approved for osteoporosis and breast cancer prevention.
  • SERMs modulate estrogen receptors (ERα, ERβ, GPER) and downstream pathways.
  • Potential neuroprotective and neuropsychiatric applications are being explored.

Purpose of the Study:

  • To review the evidence for raloxifene's neuroprotective and neuropsychiatric effects.
  • To examine its mechanisms of action, safety, and clinical limitations for CNS disorders.
  • To identify future research directions for raloxifene repurposing.

Main Methods:

  • Review of pharmacological, preclinical, and clinical studies on raloxifene.
  • Analysis of raloxifene's effects on estrogen receptors and related pathways.
  • Evaluation of evidence in Alzheimer's, Parkinson's, MS, ALS, schizophrenia, and mood disorders.

Main Results:

  • Raloxifene modulates neuroinflammation, oxidative stress, and apoptosis via estrogen receptors.
  • Preclinical studies show efficacy in models of AD, PD, MS, and ALS.
  • Positive effects observed in memory, attention, negative symptoms of schizophrenia, and mood disorders.

Conclusions:

  • Raloxifene demonstrates promise for repurposing in neurodegenerative and neuropsychiatric disorders.
  • Clinical translation is limited by small trials, heterogeneous designs, and dosing discrepancies.
  • Further research is needed on sex-specific effects, optimized dosing, and long-term efficacy.